Cargando…

A Computational Strategy to Select Optimized Protein Targets for Drug Development toward the Control of Cancer Diseases

In this report, we describe a strategy for the optimized selection of protein targets suitable for drug development against neoplastic diseases taking the particular case of breast cancer as an example. We combined human interactome and transcriptome data from malignant and control cell lines becaus...

Descripción completa

Detalles Bibliográficos
Autores principales: Carels, Nicolas, Tilli, Tatiana, Tuszynski, Jack A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308075/
https://www.ncbi.nlm.nih.gov/pubmed/25625699
http://dx.doi.org/10.1371/journal.pone.0115054
_version_ 1782354544177446912
author Carels, Nicolas
Tilli, Tatiana
Tuszynski, Jack A.
author_facet Carels, Nicolas
Tilli, Tatiana
Tuszynski, Jack A.
author_sort Carels, Nicolas
collection PubMed
description In this report, we describe a strategy for the optimized selection of protein targets suitable for drug development against neoplastic diseases taking the particular case of breast cancer as an example. We combined human interactome and transcriptome data from malignant and control cell lines because highly connected proteins that are up-regulated in malignant cell lines are expected to be suitable protein targets for chemotherapy with a lower rate of undesirable side effects. We normalized transcriptome data and applied a statistic treatment to objectively extract the sub-networks of down- and up-regulated genes whose proteins effectively interact. We chose the most connected ones that act as protein hubs, most being in the signaling network. We show that the protein targets effectively identified by the combination of protein connectivity and differential expression are known as suitable targets for the successful chemotherapy of breast cancer. Interestingly, we found additional proteins, not generally targeted by drug treatments, which might justify the extension of existing formulation by addition of inhibitors designed against these proteins with the consequence of improving therapeutic outcomes. The molecular alterations observed in breast cancer cell lines represent either driver events and/or driver pathways that are necessary for breast cancer development or progression. However, it is clear that signaling mechanisms of the luminal A, B and triple negative subtypes are different. Furthermore, the up- and down-regulated networks predicted subtype-specific drug targets and possible compensation circuits between up- and down-regulated genes. We believe these results may have significant clinical implications in the personalized treatment of cancer patients allowing an objective approach to the recycling of the arsenal of available drugs to the specific case of each breast cancer given their distinct qualitative and quantitative molecular traits.
format Online
Article
Text
id pubmed-4308075
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-43080752015-02-06 A Computational Strategy to Select Optimized Protein Targets for Drug Development toward the Control of Cancer Diseases Carels, Nicolas Tilli, Tatiana Tuszynski, Jack A. PLoS One Research Article In this report, we describe a strategy for the optimized selection of protein targets suitable for drug development against neoplastic diseases taking the particular case of breast cancer as an example. We combined human interactome and transcriptome data from malignant and control cell lines because highly connected proteins that are up-regulated in malignant cell lines are expected to be suitable protein targets for chemotherapy with a lower rate of undesirable side effects. We normalized transcriptome data and applied a statistic treatment to objectively extract the sub-networks of down- and up-regulated genes whose proteins effectively interact. We chose the most connected ones that act as protein hubs, most being in the signaling network. We show that the protein targets effectively identified by the combination of protein connectivity and differential expression are known as suitable targets for the successful chemotherapy of breast cancer. Interestingly, we found additional proteins, not generally targeted by drug treatments, which might justify the extension of existing formulation by addition of inhibitors designed against these proteins with the consequence of improving therapeutic outcomes. The molecular alterations observed in breast cancer cell lines represent either driver events and/or driver pathways that are necessary for breast cancer development or progression. However, it is clear that signaling mechanisms of the luminal A, B and triple negative subtypes are different. Furthermore, the up- and down-regulated networks predicted subtype-specific drug targets and possible compensation circuits between up- and down-regulated genes. We believe these results may have significant clinical implications in the personalized treatment of cancer patients allowing an objective approach to the recycling of the arsenal of available drugs to the specific case of each breast cancer given their distinct qualitative and quantitative molecular traits. Public Library of Science 2015-01-27 /pmc/articles/PMC4308075/ /pubmed/25625699 http://dx.doi.org/10.1371/journal.pone.0115054 Text en © 2015 Carels et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Carels, Nicolas
Tilli, Tatiana
Tuszynski, Jack A.
A Computational Strategy to Select Optimized Protein Targets for Drug Development toward the Control of Cancer Diseases
title A Computational Strategy to Select Optimized Protein Targets for Drug Development toward the Control of Cancer Diseases
title_full A Computational Strategy to Select Optimized Protein Targets for Drug Development toward the Control of Cancer Diseases
title_fullStr A Computational Strategy to Select Optimized Protein Targets for Drug Development toward the Control of Cancer Diseases
title_full_unstemmed A Computational Strategy to Select Optimized Protein Targets for Drug Development toward the Control of Cancer Diseases
title_short A Computational Strategy to Select Optimized Protein Targets for Drug Development toward the Control of Cancer Diseases
title_sort computational strategy to select optimized protein targets for drug development toward the control of cancer diseases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308075/
https://www.ncbi.nlm.nih.gov/pubmed/25625699
http://dx.doi.org/10.1371/journal.pone.0115054
work_keys_str_mv AT carelsnicolas acomputationalstrategytoselectoptimizedproteintargetsfordrugdevelopmenttowardthecontrolofcancerdiseases
AT tillitatiana acomputationalstrategytoselectoptimizedproteintargetsfordrugdevelopmenttowardthecontrolofcancerdiseases
AT tuszynskijacka acomputationalstrategytoselectoptimizedproteintargetsfordrugdevelopmenttowardthecontrolofcancerdiseases
AT carelsnicolas computationalstrategytoselectoptimizedproteintargetsfordrugdevelopmenttowardthecontrolofcancerdiseases
AT tillitatiana computationalstrategytoselectoptimizedproteintargetsfordrugdevelopmenttowardthecontrolofcancerdiseases
AT tuszynskijacka computationalstrategytoselectoptimizedproteintargetsfordrugdevelopmenttowardthecontrolofcancerdiseases